Council member Novartis is collaborating with new gene therapy company Dyno Therapeutics to its expand gene therapy research.
Novartis and Dyno will collaborate on research in treating eye diseases, specifically leveraging Dyno’s expertise in utilizing artificial intelligence in gene therapy development. The startup provides new technology in machine learning and virus research that Novartis will use to expand its gene therapy portfolio.
“We are delighted to be collaborating with Novartis,” stated , Ph.D., CEO and Co‑founder of Dyno Therapeutics. “Many eye diseases are ideally suited to being treated with gene therapies, and more opportunities can be opened with new and improved AAV vectors. With their extensive ophthalmologic expertise, Novartis is an ideal partner to leverage Dyno’s platform to design AI-powered vectors to expand the impact of gene therapies for ocular diseases.”
The Council congratulates Novartis for this innovative partnership and its pioneering work in its field. Read more in the Boston Business Journal.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022